Consensus Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:13:49 2025-04-17 pm EDT			5-day change	1st Jan Change
851.74 ^USD	+15.90%		+18.28%	+10.45%

02:11pm	Sector Update: Health Care Stocks Softer Thursday Afternoon	MT
01:47pm	Lilly weight-loss pill works as well as Ozempic, shares surge	RE

Evolution of the Average Target: Eli Lilly and Company

Evolution of the Target Price: Eli Lilly and Company

Changes in Analyst Recommendations: Eli Lilly and Company

e16cf88b0d2a3bd4e7a161ef.l1ZnkXyhVggAMaSEMJ8SWanxHQohOR57fWfF2pTQrL0.wDsU4zn4Ek9sSOzUYMVBMfqjdn1CUXZPMT-uuN2878XAGDPEOpUAXnBh5Q~42cd8c60da6b547da5baca7e121befc4

Analysts' recommendations: Eli Lilly and Company

BMO Capital Adjusts Eli Lilly Price Target to $900 From $1,010, Maintains Outperform Rating	08:38am	MT
Guggenheim Adjusts Eli Lilly and Co.'s PT to $928 From $973, Keeps Buy Rating	Apr. 14	MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,124 From $1,146, Keeps Overweight Rating	Apr. 09	MT
Redburn Atlantic Adjusts Price Target on Eli Lilly and Company to $800 From $700, Keeps Neutral Rating	Mar. 18	MT
Wells Fargo Adjusts Price Target on Eli Lilly and Company to $1,100 From $970, Keeps Overweight Rating	Mar. 05	MT
TD Cowen Adjusts Price Target on Eli Lilly and Company to $1,050 From $900, Maintains Buy Rating	Mar. 04	MT
Argus Adjusts Price Target on Eli Lilly to $1,000 From $980	Feb. 20	MT
DBS Bank Adjusts Eli Lilly Price Target to $1,010 From $900	Feb. 18	MT
CICC Adjusts Price Target on Eli Lilly and Company to $874 From $832, Keeps Neutral Rating	Feb. 13	MT
Daiwa Securities Adjusts Eli Lilly Price Target to $940 From $900, Maintains Outperform Rating	Feb. 10	MT
Leerink Partners Adjusts Eli Lilly and Company's Price Target to $989 From $950	Feb. 07	MT
Analysts recommendations: Aj Bell, GSK, Anglo American, Eli Lilly, Expedia…	Feb. 07
Analysts recommendations: Air Products & Chemicals, AMD, Elf Beauty, Eli Lilly, Expedia…	Feb. 07
Deutsche Bank Adjusts Price Target on Eli Lilly to $1,010 From $1,015	Feb. 04	MT
Truist Securities Adjusts Eli Lilly Price Target to $1,038 From $1,029, Maintains Buy Rating	Feb. 03	MT
Citigroup Adjusts Price Target on Eli Lilly and Company to $1,190 From $1,250, Keeps Buy Rating	Jan. 28	MT
Wells Fargo Adjusts Price Target on Eli Lilly and Company to $970 From $1,000, Keeps Overweight Rating	Jan. 28	MT
DBS Bank Adjusts Price Target on Eli Lilly to $900 From $1,115, Maintains Buy Rating	Jan. 24	MT
Jefferies Adjusts Price Target on Eli Lilly to $1,020 From $996	Jan. 22	MT
Guggenheim Adjusts Price Target on Eli Lilly to $973 From $995, Maintains Buy Rating	Jan. 17	MT
Berenberg Bank Adjusts Eli Lilly Price Target to $970 From $1,050, Maintains Buy Rating	Jan. 16	MT
TD Cowen Adjusts Price Target on Eli Lilly to $900 From $1,050, Maintains Buy Rating	Jan. 16	MT
Leerink Partners Adjusts Price Target on Eli Lilly to $950 From $970, Keeps Outperform Rating	Jan. 15	MT
Jefferies Adjusts Price Target on Eli Lilly to $996 From $994	Jan. 14	MT
ELI LILLY AND COMPANY : Jefferies gives a Buy rating	Dec. 20	ZD

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	ELI LILLY AND COMPANY					+37.28%
	JOHNSON & JOHNSON					+10.56%
	ABBVIE INC.					+22.86%
	NOVO NORDISK A/S					+74.16%
	ROCHE HOLDING AG					+23.19%
	ASTRAZENECA PLC					+32.58%
	NOVARTIS AG					+6.31%
	MERCK & CO., INC.					+45.02%
	AMGEN INC.					+12.2%
	GILEAD SCIENCES, INC.					+7.27%
	Average					+27.14%
	Weighted average by Cap.					+29.66%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

734.90USD

Average target price

1,004.66USD

Spread / Average Target

+36.71%

High Price Target

1,190.00USD

Spread / Highest target

+61.93%

Low Price Target

650.00USD

Spread / Lowest Target

-11.55%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Guggenheim
Morgan Stanley
Redburn Atlantic
Wells Fargo Securities
TD Cowen
Argus
DBS Bank
CICC Research
Daiwa Securities
Leerink Partners
Deutsche Bank Securities
Truist Securities
Citigroup
Jefferies & Co.
Berenberg Bank
JEFFERIES	Akash Tewari
BofA Securities
Barclays
BMO Capital
Goldman Sachs
Bernstein
JPMorgan Chase
China International Capital
Wolfe Research
UBS
DZ Bank
Cantor Fitzgerald
Morningstar
Credit Suisse
HSBC
SVB Securities LLC
Cowen
Mizuho Securities